Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114471 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xiujie Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China; N…. Hauptthemen laut MEDLINE: Metformin, Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Zhejiang Province Public Welfare Technology Application Research Project.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD), a prevalent chronic liver disease, poses a substantial global health burden. Metformin is known for its protective effects in NAFLD, but the role of gut microbiota in the underlying mechanisms remains unclear. In this study, metformin was found to mitigate methionine-choline deficient (MCD) -diet induced NAFLD through reshaping the gut microbiota to increase ursodeoxycholic acid (UDCA) level, thereby inhibiting farnesoid X receptor (FXR) accompanied with activated autophagy. Specifically, using dirty cage experiments and 16S rRNA sequencing, it identified that metformin could reshape microbiota to release liver injury as confirmed by the results of histopathology and biochemical index detection. Furthermore, the bile acids were found to be altered by metformin, in which, the UDCA, a FXR natural inhibitor, was observed a significantly increase. Meanwhile, the inhibited FXR and activated autophagy in metformin-treated mice were captured using western blot, qRT-PCR and immunofluorescence analysis. In addition, the benefit of UDCA against NAFLD was demonstrated in UDCA treated mice. Further investigation with FXR siRNA introduced to HepG2 cells revealed that inhibiting FXR can reduce oleic acids induced cell injury with the autophagy activation. In conclusion, this study highlights metformin's potential to ameliorate NAFLD by reshaping gut microbiota, thereby upregulating UDCA in the liver and restoring cholesterol synthesis capacity, possibly via inhibiting FXR to activate autophagy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China; Nottingham Ningbo China Beacons of Excellence Research and Innovation I…
- Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China.
- Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China. Electronic address: jinkeke@wmu.edu.cn.
- Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo 315048, Zhejiang, China.
- Oncology Department, Shunde Hospital of Guangzhou University of Chinese Medicine, Guangdong 528300, China; Research Center of Translational Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, Guangdon…
- Institute of microbiota and host inflammation-related diseases; School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China. Electronic address: fangyan_wang@wmu.edu.cn.
Förderung
- Zhejiang Province Public Welfare Technology Application Research Project
Zitieren
APA
Liu, X., Sun, H., Han, Q., Wang, Z., Zeng, J., Liu, J., Ou, S., Jin, K., Shao, Y., Li, D., Gao, Z., & Wang, F. (2025). Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114471
Vancouver
Liu X, Sun H, Han Q, Wang Z, Zeng J, Liu J, et al. Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114471
BibTeX
@article{Liu2025,
author = {Liu, Xiujie and Sun, Hongxia and Han, Qiannian and Wang, Zekai and Zeng, Jingjing and Liu, Jianwei and Ou, Shining and Jin, Keke and Shao, Yuanyuan and Li, Dongbing and Gao, Zhuowei and Wang, Fangyan},
title = {Gut microbiota-derived UDCA enhanced by metformin inhibits FXR to activate autophagy against MCD diet-induced NAFLD in mice},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114471}
}
EUVIMED